The Phase 1b/2 CARTITUDE-1 is an ongoing, single-arm, open-label, multicenter clinical study involving 16 centers in the US and enrolled 97 patients to evaluate the safety and efficacy of cilta-cel in adults with r/r MM who received ≥3 prior LOT, including a proteasome inhibitor (PI), an immunomodulatory drugs (IMiDs), and anti-CD38 mAb (12). The gene discussed is CD38; the disease is Miyoshi myopathy.